Cell Transplantation for Drug-Resistant Epilepsy (NTE-001) NRTX-1001 - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental cell therapy called NRTX-1001 (the study drug) is a safe and effective treatment for drug-resistant mesial temporal lobe epilepsy (MTLE). We want to know if the study drug can reduce seizures in people who are not getting relief from conventional treatments.

What is the Condition Being Studied?

Mesial Temporal Lobe Epilepsy

Who Can Participate in the Study?

Adults ages 18-65 who:

Are diagnosed with temporal lobe epilepsy that causes focal seizures
Have tried at least 2 different medications to control seizures without success
Are having at least 2 seizures per month for the past 6 months
Do not have an indwelling intracranial device (shunt, neurostimulator, etc.) placed in the brain
Have never received any type of gene or cell therapy

For more information about who can join this study, please contact the study team at Jodi.Lennon@duke.edu or 919-613-9129.

Age Group

Adults

What is Involved?

If you choose to join this study, you will:

Have a surgical procedure to introduce a population of cells into the part of your brain that causes your seizures
Take immunosuppressant medication (medicines that reduce the immune system) before you have the surgical procedure and for up to 1 year after the procedure is done
Have blood draws
Have imaging scans (EEG & MRI)

After the procedure is done, you will return to our clinic annually for follow-up study visits (years 3-15). We will continue to keep in touch with you (phone calls every 3 months) during years 3-15.

You can find more information about this study on its website: https://www.neuronatherapeutics.com/nte001/